BG63805B1 - Получаване на [1s-(1а,2в,3в,4а(s*)]-4-[7-[[[1-(3-хлор-2-тиенил) метил]пропил]амино]-3н-имидазо[4,5-в]пиридин-3-ил]-n-етил- 2,3-дихидроксициклопентан карбоксамид - Google Patents

Получаване на [1s-(1а,2в,3в,4а(s*)]-4-[7-[[[1-(3-хлор-2-тиенил) метил]пропил]амино]-3н-имидазо[4,5-в]пиридин-3-ил]-n-етил- 2,3-дихидроксициклопентан карбоксамид Download PDF

Info

Publication number
BG63805B1
BG63805B1 BG103484A BG10348499A BG63805B1 BG 63805 B1 BG63805 B1 BG 63805B1 BG 103484 A BG103484 A BG 103484A BG 10348499 A BG10348499 A BG 10348499A BG 63805 B1 BG63805 B1 BG 63805B1
Authority
BG
Bulgaria
Prior art keywords
amino
chloro
thienyl
methyl
propyl
Prior art date
Application number
BG103484A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG103484A (en
Inventor
Michael O'brian
Herve Garcia
Patrick Leon
Tory POWNER
Laurence REILLY
Harshavadan SHAH
Michael Thompson
Ching TSUEI
Benoit VANASSE
Francis WALTHER
Original Assignee
Rhone-Poulenc Rorer Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone-Poulenc Rorer Pharmaceuticals Inc. filed Critical Rhone-Poulenc Rorer Pharmaceuticals Inc.
Publication of BG103484A publication Critical patent/BG103484A/xx
Publication of BG63805B1 publication Critical patent/BG63805B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
BG103484A 1996-12-11 1999-06-11 Получаване на [1s-(1а,2в,3в,4а(s*)]-4-[7-[[[1-(3-хлор-2-тиенил) метил]пропил]амино]-3н-имидазо[4,5-в]пиридин-3-ил]-n-етил- 2,3-дихидроксициклопентан карбоксамид BG63805B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3276496P 1996-12-11 1996-12-11
PCT/US1997/021439 WO1998025921A1 (en) 1996-12-11 1997-11-24 PREPARATION OF [1S-[1a,2b,3b,4a(S*)]]-4-[7-[[1-(3-CHLORO-2-THIENYL) METHYL]PROPYL]AMINO]-3H-IMIDAZO[4,5-b]PYRIDIN-3-yl]-N-ETHYL-2,3-DIHYDROXYCYCLOPENTANECARBOXAMIDE

Publications (2)

Publication Number Publication Date
BG103484A BG103484A (en) 2000-06-30
BG63805B1 true BG63805B1 (bg) 2003-01-31

Family

ID=21866680

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103484A BG63805B1 (bg) 1996-12-11 1999-06-11 Получаване на [1s-(1а,2в,3в,4а(s*)]-4-[7-[[[1-(3-хлор-2-тиенил) метил]пропил]амино]-3н-имидазо[4,5-в]пиридин-3-ил]-n-етил- 2,3-дихидроксициклопентан карбоксамид

Country Status (27)

Country Link
US (2) US6143894A (es)
EP (2) EP1609791A1 (es)
JP (1) JP2001506626A (es)
KR (4) KR100510389B1 (es)
CN (3) CN1191251C (es)
AP (1) AP1063A (es)
AT (1) ATE301120T1 (es)
AU (1) AU738581B2 (es)
BG (1) BG63805B1 (es)
BR (1) BR9713705A (es)
CA (1) CA2274630C (es)
DE (1) DE69733897T2 (es)
DK (1) DK0946550T3 (es)
EA (1) EA001989B1 (es)
ES (1) ES2242984T3 (es)
HK (2) HK1023998A1 (es)
HU (1) HUP0000342A3 (es)
IL (1) IL130397A (es)
MX (1) MXPA03006730A (es)
NO (2) NO319722B1 (es)
OA (1) OA11061A (es)
PT (1) PT946550E (es)
SI (1) SI0946550T1 (es)
SK (1) SK71199A3 (es)
UA (1) UA54479C2 (es)
WO (1) WO1998025921A1 (es)
ZA (1) ZA9711035B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1140933T1 (en) 1998-12-31 2005-02-28 Aventis Pharmaceuticals Inc. Process for preparing n6-substituted deaza-adenosine derivatives
US7291603B2 (en) * 2002-07-24 2007-11-06 Ptc Therapeutics, Inc. Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
FR2846656B1 (fr) * 2002-11-05 2004-12-24 Servier Lab Nouveaux derives d'imidazopyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2505085B2 (ja) * 1990-09-25 1996-06-05 ローヌ−プーラン ローラー インターナショナル （ホウルディングス） インコーポレイテッド 抗昇圧および抗虚血特性を有する化合物
AU746706B2 (en) * 1997-07-03 2002-05-02 Du Pont Pharmaceuticals Company Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
EA003645B1 (ru) * 1998-12-21 2003-08-28 Авентис Фармасьютикалз Инк. Способ получения n6-замещенных производных деаза-аденозина

Also Published As

Publication number Publication date
NO20052327L (no) 1999-08-10
CN1090630C (zh) 2002-09-11
AP1063A (en) 2002-04-26
PT946550E (pt) 2005-09-30
HK1023998A1 (en) 2000-09-29
DK0946550T3 (da) 2005-08-29
MXPA03006730A (es) 2003-10-24
US6143894A (en) 2000-11-07
KR20050046793A (ko) 2005-05-18
UA54479C2 (uk) 2003-03-17
WO1998025921A1 (en) 1998-06-18
IL130397A (en) 2005-11-20
BR9713705A (pt) 2000-05-09
NO319722B1 (no) 2005-09-05
EP0946550A4 (en) 2003-05-14
DE69733897T2 (de) 2006-06-01
AU5360798A (en) 1998-07-03
KR20060002030A (ko) 2006-01-06
EP0946550A1 (en) 1999-10-06
OA11061A (en) 2002-02-27
BG103484A (en) 2000-06-30
NO992795L (no) 1999-08-10
KR20000057505A (ko) 2000-09-15
IL130397A0 (en) 2000-06-01
CN1394859A (zh) 2003-02-05
NO992795D0 (no) 1999-06-09
EA001989B1 (ru) 2001-10-22
CA2274630C (en) 2000-10-03
CN1240445A (zh) 2000-01-05
SK71199A3 (en) 2000-07-11
SI0946550T1 (en) 2005-10-31
EA199900527A1 (ru) 2000-02-28
CN1191251C (zh) 2005-03-02
HUP0000342A3 (en) 2001-01-29
ATE301120T1 (de) 2005-08-15
AP9901550A0 (en) 1999-06-30
KR100571690B1 (ko) 2006-04-18
AU738581B2 (en) 2001-09-20
NO20052327D0 (no) 2005-05-12
KR100510389B1 (ko) 2005-08-31
KR20060002029A (ko) 2006-01-06
ES2242984T3 (es) 2005-11-16
JP2001506626A (ja) 2001-05-22
US6235909B1 (en) 2001-05-22
ZA9711035B (en) 1998-06-15
CN1660842A (zh) 2005-08-31
DE69733897D1 (de) 2005-09-08
EP0946550B1 (en) 2005-08-03
HUP0000342A2 (hu) 2000-10-28
EP1609791A1 (en) 2005-12-28
HK1051862A1 (en) 2003-08-22

Similar Documents

Publication Publication Date Title
EP2235001B1 (en) Process for preparing pyridinone compounds
JP2017522306A (ja) ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの製造方法
CN104662002A (zh) 取代脲类化合物的合成方法
BG63805B1 (bg) Получаване на [1s-(1а,2в,3в,4а(s*)]-4-[7-[[[1-(3-хлор-2-тиенил) метил]пропил]амино]-3н-имидазо[4,5-в]пиридин-3-ил]-n-етил- 2,3-дихидроксициклопентан карбоксамид
EP1655297A1 (en) Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
CN110003101B (zh) 一种阿帕替尼中间体及其制备方法
CN109879805B (zh) 阿帕替尼的制备方法
US11739088B2 (en) Synthesis of heterocyclic compounds
IL152921A (en) Preparation of 4-hydroxy-3-nitro-2(1h)-pyridone from 2-hydroxy-3-cyano-4-methoxypyridine
JPH0635458B2 (ja) ピリドンカルボン酸誘導体、そのエステルおよびその塩
MXPA99005488A (es) Preparacion de [1s-[1a, 2b, 3b, 4a(s*)]]-4-[7-[[1-(3-cloro-2-tienil)metil]propil]amino]-3h-imidazo[4,5b]piridin-3-il]-n-etil-2,3-dihidroxiciclopentanocarboxamida
TW202313600A (zh) 一種ｂ肝病毒核衣殼抑制劑的製備方法
CN117658986A (zh) Ar拮抗剂trc-253的制备方法
JP2002533343A (ja) Ｎ６−置換デアザアデノシン誘導体を製造する方法
KR100359151B1 (ko) 2환성 아미노기로 치환된 피리돈카르복실산 유도체, 그의 에스테르 및 그의 염 및 이들의 중간체인 2환성 아민
AU2345299A (en) Processes and intermediates useful to make antifolates
CZ208599A3 (cs) Způsob přípravy [lS-[la,2b,3b,4a(S)]]-4-[7-[[l- (3-Cloro-2-thienyl) methyl]propyl]amino]-3Himidazo[4,5-b]pyridin-3-yl]-N-ethyl-2,3- dihydroxycyklopentankarbokamidu
JP2007284416A (ja) 光学活性なピペラジン化合物の製造方法
CZ20002962A3 (cs) Způsob a meziprodukty, použitelné k přípravě antifolátů